Euroasian Journal of Hepato-Gastroenterology

Register      Login

VOLUME 5 , ISSUE 1 ( January-June, 2015 ) > List of Articles

REVIEW ARTICLE

Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update

Andrew Ofosu, Ahmet Gurakar

Citation Information : Ofosu A, Gurakar A. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update. Euroasian J Hepatogastroenterol 2015; 5 (1):19-25.

DOI: 10.5005/jp-journals-10018-1123

License: CC BY-NC 4.0

Published Online: 01-01-2015


Abstract

Hepatocellular carcinoma (HCC) is the fifth most common cancer worldwide. Multiple treatment modalities for HCC are available, depending on size and number of tumor. Liver transplantation offers the most reasonable option for curative treatment, because it simultaneously removes the burden of the diseased liver. The Milan criteria currently remain the benchmark for the selection of patients with HCC for transplantation. However, there is considerable and promising interest in expanding the eligibility criteria to include the University of California San Francisco criteria. Liver transplantation (LT) has progressed during the past decade. The introduction of living donor LT has provided a means of expanding organ transplant, but with some inherent concerns. Herein, we reviewed the diagnosis and management of HCC with emphasis on the current concepts of liver transplantation for the treatment of HCC.


PDF Share
  1. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362(9399):1907-1917
  2. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127(5 Suppl 1): S5-S16
  3. Management of hepatocellular carcinoma: an update. Hepatology 2011;53(3):1020-1022
  4. Treatment of intermediate/ advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010;15(Suppl 4):42-52
  5. Resection or transplantation for hepatocellular carcinoma in cirrhotic patients: outcomes based on indicated treatment strategy. J Am Coll Surg 2000;190(5):580-587
  6. Hepatocellular carcinoma—United States, 2001-2006. MMWR Morb Mortal Wkly Rep 2010;59(17):517-520
  7. Global cancer statistics, 2002. CA Cancer J Clin 2005;55(2):74-108
  8. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10): 745-750
  9. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991 Nov;350(6317):427-428
  10. Coffee reduces risk for hepatocellular carcinoma: an updated meta-analysis. Clin Gastroenterol Hepatol 2013 Nov;11(11):1413-1421
  11. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Natl Cancer Inst 2012;104(15):1173-1181
  12. EASLEORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56(4):908
  13. Comparison of liver biopsy and noninvasive methods for diagnosis of hepatocellular carcinoma. Clin Gastroenterol Hepatol 2006; 4(3):361-368
  14. Biopsy of suspicious liver nodules: does it change management? Clin Gastroenterol Hepatol 2006;4(3):296-298
  15. Serum alpha-fetoprotein and its lectin reactivity in liver diseases: a review. Ann Clin Lab Sci 1990;20(2):98-105
  16. Characteristics of fibrolamellar hepatocellular carcinoma: a study of nine cases and a review of the literature. Am J Surg 1986;151(4):518-523
  17. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16(3): 262-278
  18. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008;134(5):1342-1351
  19. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma. J Hepatol 2012;56(6):1371-1383
  20. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985;56(4):918-928
  21. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 2000;31(4):840-845
  22. American Joint Committee on Cancer Staging Manual. 7th ed. In: Edge SB, Byrd DR, Compton CC, et al, editors. Springer, New York; 2010. p. 175. Current Concepts in Hepatocellular Carcinoma and Liver Transplantation: A Review and 2014 Update Euroasian Journal of Hepato-Gastroenterology, January-June 2015;5(1):19-25 25 EJOHG 23. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19(3):329-338
  23. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 2005;41(4):707-716
  24. Barcelona clinic liver cancer staging and transplant survival benefit for patients with hepatocellular carcinoma: a multicentre, cohort study. Lancet Oncol 2011;12(7):654-662
  25. Pretreatment assessment of hepatocellular carcinoma: expert consensus statement. HPB (Oxford) 2010;12(5):289-299
  26. Hepatic transplantation for primary and metastatic cancers of the liver. Surgery 1991;110(4):726-734
  27. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 1991;15(2):270-285
  28. Hepatocellular carcinoma: comparison between liver transplantation, resective surgery, ethanol injection and chemoembolization. Transpl Int 1998;11(Suppl 1):S193-S196
  29. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993;218(2): 145-151
  30. Survival and recurrence after liver transplantation versus liver resection for hepatocellular carcinoma: a retrospective analysis. Ann Surg 1998;227(3):424-432
  31. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-699
  32. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33(6): 1394-1403
  33. Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10(1):35-43
  34. Sa1027, clinical indicator of microvascular invasion in hepatocellular carcinoma: when Milan is not enough. Gastroenterology 2014; 5:S-941
  35. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann Surg 2008;248(4):617-625
  36. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48(3):819-827
  37. Benefit of downsizing hepatocellular carcinoma in a liver transplant population. Aliment Pharmacol Ther 2010;31(3):415-423
  38. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8(12):2547-2557
  39. Downstaging disease in patients with hepatocellular carcinoma outside of Milan criteria: strategies using drug-eluting bead chemoembolization. J Vasc Interv Radiol 2013;24(11):1613-1622
  40. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma. Aliment Pharmacol Ther 2013;37(4):411-419
  41. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 2009;10(1): 25-34
  42. Reduced mortality with right-lobe living donor compared to deceased-donor liver transplantation when analyzed from the time of listing. Am J Transplant 2007;7(4):998-1002
  43. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007;7(6): 1601-1608.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.